LaunchPort’s Novel Microdevices Lands Important Funding from Carb-X Global Partnership
Apr 6, 2021
- No Comments
Novel Microdevices (https://noveldx.com/) was awarded up to $13.8 million from CARB-X (https://carb-x.org/) for the development of a rapid, point-of-care, molecular diagnostic platform for the detection of sexually transmitted diseases, including antibiotic-resistant infections such as Chlamydia trachomatis and Neisseria gonorrhoeae. Novel’s new device would diagnose infections in about 25 minutes from a vaginal swab or urine sample, and […]
Read More